Micro-Caps — page 9
AIRO Restores Operating Profit After First-Quarter Loss
Second-quarter revenue reached $43.2 million, up 76% from a year earlier, and gross margin recovered to 64%.
S-3 Shelf Push Reaches Six Issuers
Six companies sought accelerated effectiveness for Form S-3 shelf registrations in 2026, with four requests clustered in May after two earlier winter requests.
Sutro Reports Early STRO-004 Responses in Phase 1
The company posted $9.8 million of second-quarter revenue and $164.3 million of cash as it optimized STRO-004 between 4 and 5 mg/kg.
M-tron's Adjusted EBITDA Growth Accelerates
Adjusted EBITDA rose 40.6% to $3.4 million in the three months ended June 30, 2026, as backlog reached $84.0 million.
Lexeo Starts LX2006 Pivotal Trial, Wins RMAT for LX2020
Cash, cash equivalents and investments were $234.2 million as of June 30, 2026, which the company said it expects to fund operations into 2028.
Century Therapeutics Locks In CNTY-813 IND Path After FDA Meeting
Cash, cash equivalents, and investments were $197.2 million as of June 30, 2026, with runway still estimated into the first quarter of 2029.
Humacyte ATEV Beats Fistula in Dialysis Trial
The company plans a supplemental BLA in the second half of 2026 after women on the vessel gained 91 more catheter-free days than those on AV fistula.
Cypherpunk Aligns With FDA on Sirexatamab Phase 3
The privacy-technology company posted $39.4 million of second-quarter net income as its Zcash treasury reached 323,394.38 ZEC.
Ambiq Posts Record Sales, Signals Slower Growth
Second-quarter net sales reached $33.901 million, topping Ambiq’s previous guidance ceiling by $1.901 million.
Neuronetics Turns Adjusted Ebitda Positive in Second Quarter
Greenbrook clinics posted $26.9 million of revenue as the interventional mental-health company swung to a $0.3 million adjusted Ebitda profit.
Smart Sand Raises Annual Volume Growth Forecast
Smart Sand reported record quarterly revenue of $115.1 million and raised its forecast for annual sand sales-volume growth.
Sanara MedTech Agrees to Be Acquired by MIMEDX
Second-quarter net revenue was $28.1 million as year-over-year growth slowed to 9% from 19% in the first quarter.
Microvast Sequential Sales Recover After First-Quarter Drop
Second-quarter revenue was $87.3 million, with $2.7 million of IEEPA tariff refunds booked as a cut to sales.
Immunic Names Lundgren Chief Executive Officer
The late-stage biotech ended June with $155.1 million in cash after a February private placement and said ENSURE top-line data are expected by the end of 2026.
Inhibikase Starts 43 Sites After 26-Country Trial Approvals
Cash, cash equivalents and marketable securities were $159.0 million at June 30, 2026, after a $50 million RA Capital sale in July.
Codexis Reiterates 2026 Outlook After July Equity Raise
The enzymatic-therapeutics maker booked $14.9 million of second-quarter revenue and said proforma cash of about $80 million will fund operations through the end of 2028.
Black Rock Coffee Bar Raises 2026 Opening and Ebitda Targets
The company lifted full-year 2026 adjusted EBITDA to $34 million to $35 million and store openings to 38 after a 25.0% year-over-year revenue increase.
Unusual Machines to Buy Upgrade Energy in $52 Million Cash-and-Stock Deal
The acquisition would add domestic battery engineering and manufacturing capacity to the drone-component maker.
Cost Inflation Outruns Relief Across 14 Industries
Of 126 companies reporting on the domestic economy this week, 42 across 11 industries pointed to pricing and cost pressure as the defining issue, from oilfield services to hardware to real estate.
Telos Raises Full-Year Profit Outlook on Telos ID
Second-quarter revenue reached $47.7 million, up 33% from a year earlier, and the company lifted full-year Adjusted EBITDA to as much as $28.6 million.
Outdoor Holding Extends Revenue Growth as Profitability Widens
Net revenues rose 22.1% to $14.5 million in the fiscal first quarter ended June 30, 2026, and Adjusted EBITDA more than doubled to $7.9 million.
PennantPark’s Net Asset Value Decline Slows
Net asset value fell 2.5% in the June quarter, while investment earnings remained below the company’s combined base and supplemental distributions.
Palisade Bio Clears IND and Starts Phase 2 Ulcerative Colitis Trial
Cash and cash equivalents stood at $125.2 million as of June 30, 2026, which the company said is sufficient through Phase 2 readouts expected in the second half of 2027 and early 2028.
MITT Signs Cherry Hill Merger After Book Value Recovers
The residential mortgage REIT posted $0.24 of earnings available for distribution a share, matching its dividend, and lifted book value to $10.00.
James River Cuts Specialty Admitted Premiums to Chase E&S
Gross written premium fell 29% to $268.9 million as Specialty Admitted collapsed 76% and group retention rose to 55%.
GoPro Board Authorizes Sale Process as Revenue Falls
Second-quarter revenue was $105 million, down 31% from a year earlier, as hardware sales and retail demand continued to contract.
Greystone Housing Impact Investors Posts a Net Loss
Cash available for distribution was $2.43 million, or $0.10 a BUC, as the partnership booked a $1.52 million net loss.
FutureFuel Returns to Profit With Hedging Benefit
FutureFuel reported second-quarter net income of $11.4 million, reversing losses as biofuel production recovered and hedge-related timing benefits lifted gross profit.
Energy Services of America Raises Dividend After Profit Jump
Net income reached $3.3 million, or $0.18 a share, and the quarterly dividend rose 33% to $0.04 a share.
Crescent BDC NAV Falls Again After Fee Cuts
Net investment income was $0.36 a share in the quarter ended June 30, 2026, and NAV per share was $17.82.